| Literature DB >> 31176273 |
Stefania Gori1, Massimo Barberis2, Maria Angela Bella3, Fiamma Buttitta4, Ettore Capoluongo5, Paola Carrera6, Nicoletta Colombo7, Laura Cortesi8, Maurizio Genuardi9, Massimo Gion10, Valentina Guarneri11, Lorena Incorvaia12, Nicla La Verde13, Domenica Lorusso14, Antonio Marchetti15, Paolo Marchetti16, Nicola Normanno17, Barbara Pasini18, Matilde Pensabene19, Sandro Pignata20, Paolo Radice21, Enrico Ricevuto22, Anna Sapino23, Pierosandro Tagliaferri24, Pierfrancesco Tassone25, Chiara Trevisiol26, Mauro Truini27, Liliana Varesco28, Antonio Russo29.
Abstract
The current availability of new Poly(ADP-ribose) Polymerase (PARP)-inhibitors for the treatment of ovarian cancer patients independently of the presence of a BRCA pathogenic variant, together with the validation of somatic test for the analysis of BRCA1/2 genes, involves the need to optimise the guidelines for BRCA testing. The AIOM-SIGU-SIBIOC-SIAPEC-IAP Italian Scientific Societies, in this position paper, recommend the implementation of BRCA testing with 2 main objectives: the first is the identification of ovarian cancer patients with higher probability of benefit from specific anticancer treatments (test for response to therapy); the second goal, through BRCA testing in the family members of ovarian cancer patients, is the identification of carriers of pathogenic variant, who have inheredited predisposition to cancer development (test for cancer risk). These individuals with increased risk of cancer, should be encouraged to participate in dedicated high-risk surveillance clinics and specific risk-reducing measures (primary and/or secondary prevention programs).Entities:
Keywords: BRCA1; BRCA2; Genetic testing; Germline mutations; Ovarian cancer; PARP inhibitors; Somatic mutations
Mesh：
Substances：
Year: 2019 PMID： 31176273 DOI： 10.1016/j.critrevonc.2019.05.012
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312